Interphase cytogenetics of prostate cancer: fluorescence in situ hybridisation (FISH) analysis of Japanese cases
- PMID: 8956780
- PMCID: PMC2077208
- DOI: 10.1038/bjc.1996.617
Interphase cytogenetics of prostate cancer: fluorescence in situ hybridisation (FISH) analysis of Japanese cases
Abstract
No numerical aberration of chromosomes that might be specific for prostate cancer has so far been established. We used fluorescence in situ hybridisation (FISH) with centromere-specific probes for chromosomes 7, 8, 17, X and Y to establish the distribution of centromere copy numbers in frozen-stored or freshly prepared samples of benign prostate hypertrophy (BPH) and to detect numerical aberrations of these chromosomes in 28 prostate cancers from Japanese men. There was no significant difference in the data of centromere copy numbers between fresh and frozen-stored tissue. The most common aberration in prostate cancers was a gain of chromosome 8 (57%), with numerical aberration of chromosome 7 being the second most frequent anomaly (50%). Numerical aberration of chromosome 7 is most significantly associated with a higher Gleason score (GS) (P < 0.005) or with lymph node metastasis (P < 0.001). Numerical aberration of several chromosomes, including chromosomes 7 and/or 8, was common in aggressive prostate cancers. Loss of chromosome Y was detected in only 4% of cases. FISH analysis thus proved to be a useful method for detecting numerical aberrations of individual chromosomes, with application to touch preparations of frozen-stored tissue having the advantage of exact sampling of cancer foci. The results suggest that numerical aberration of chromosome 7 is associated with aggressive tumour behaviour and poor prognosis of patients with prostate cancer. The association between genetic change and chromosomal abnormality should be studied in detail.
Similar articles
-
DNA in situ hybridization (interphase cytogenetics) versus comparative genomic hybridization (CGH) in human cancer: detection of numerical and structural chromosome aberrations.Acta Histochem. 2000 Feb;102(1):85-94. doi: 10.1078/0065-1281-00540. Acta Histochem. 2000. PMID: 10726167
-
Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.Lab Invest. 1997 Nov;77(5):437-48. Lab Invest. 1997. PMID: 9389787
-
Gain and loss of chromosomes 1, 7, 8, 10, 18, and Y in 46 prostate cancers.Hum Pathol. 1996 Jul;27(7):720-7. doi: 10.1016/s0046-8177(96)90404-9. Hum Pathol. 1996. PMID: 8698318
-
DNA ploidy in prostate cancer: potential measurement as a surrogate endpoint biomarker.J Cell Biochem Suppl. 1994;19:246-8. J Cell Biochem Suppl. 1994. PMID: 7529855 Review.
-
Potential markers of aggressiveness in prostatic intraepithelial neoplasia detected by fluorescence in situ hybridization.Eur Urol. 1996;30(2):177-84. doi: 10.1159/000474167. Eur Urol. 1996. PMID: 8875198 Review.
Cited by
-
Molecular pathology of prostate cancer.J Clin Pathol. 2005 Jul;58(7):673-84. doi: 10.1136/jcp.2002.003954. J Clin Pathol. 2005. PMID: 15976331 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical